Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

The American Gastroenterological Association Research Foundation has announced its 2011 research scholars. The grants have been awarded to four outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

6 May 2011

Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011

Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.

3 May 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

White youths less likely to be tested for STI in pediatric emergency department

When adolescent females visit a pediatric emergency department with complaints that may signal a sexually transmitted infection, white youths are less likely to be tested than blacks, according to a study to be presented Saturday, April 30, at the Pediatric Academic Societies annual meeting in Denver.

30 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

IBD patients at greater risk of death if infected with Clostridium difficile

Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness.

20 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

AHRQ finds 52% increase in medication side effects, injuries between 2004 and 2008

The number of people treated in U.S. hospitals for illnesses and injuries from taking medicines jumped 52 percent between 2004 and 2008 - from 1.2 million to 1.9 million - according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

15 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

PUMA-mediated intestinal apoptosis contributes to ulcerative colitis in humans, mice

Ulcerative colitis is an inflammatory bowel disease thought to be related to aberrant activation of the immune system in the intestine. Recent research has also suggested that regulated cell death of the intestinal epithelial cells is a contributing factor to the pathogenesis.

2 Apr 2011

New discovery on IL-23 can lead to novel IBD treatments

A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.

1 Apr 2011

Inflammatory bowel disease in children - Delays in diagnosis common

Once a medical rarity in children, inflammatory bowel disease today is increasingly common in kids, but many of them may not be diagnosed in a timely manner, according to experts from the Pediatric Inflammatory Bowel Disease Center at Johns Hopkins Children’s Center.

28 Mar 2011

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat oral mucositis

NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.

23 Mar 2011

Gastroenterologist directs new Crohn's and Colitis Program at UT Southwestern

Dorothy Stockstill was taking eight pills a day, and her severe abdominal pain and persistent diarrhea weren't improving. The Denton resident had seen multiple physicians throughout the Dallas area. Her attacks were so severe, she couldn't successfully travel from the front of a retail store to the restrooms in back.

23 Mar 2011

Children and youth with IBD have 25% lower aerobic fitness levels

Children and adolescents growing up with inflammatory bowel disease are less fit than their peers, says a study by researchers at McMaster University and the McMaster Children's Hospital.

17 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011